| 今开：12.21 | 昨收：11.95 |
| 最高：13.3421 | 最低：11.88 |
| 涨停价：0.0 | 跌停价：0.0 |
| 总市值：9.3186311E7 |
Cidara Therapeutics(CDTX)05-01 04:15
$Cidara Therapeutics(CDTX)$ 3 Initial statement of beneficial ownership of securities Accession Number: 0001610618-24-000061 Size: 3 KB 网页链接查看全文
Cidara Therapeutics(CDTX)05-01 04:15
$Cidara Therapeutics(CDTX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001610618-24-000064 Size: 5 KB 网页链接查看全文
Cidara Therapeutics(CDTX)04-30 05:05
$Cidara Therapeutics(CDTX)$ 8-K/A [Amend] Current report, items 1.01, 1.02, 2.01, and 9.01 Accession Number: 0001610618-24-000054 Act: 34 Size: 1 MB 网页链接查看全文
Cidara Therapeutics(CDTX)05-24 05:05
$Cidara Therapeutics(CDTX)$ PRE 14A Other preliminary proxy statements Accession Number: 0001610618-24-000081 Act: 34 Size: 2 MB 网页链接查看全文
Cidara Therapeutics(CDTX)06-04 04:45
$Cidara Therapeutics(CDTX)$ DEF 14A Other definitive proxy statements Accession Number: 0001610618-24-000087 Act: 34 Size: 14 MB 网页链接查看全文
Cidara Therapeutics(CDTX)06-04 04:45
$Cidara Therapeutics(CDTX)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0001610618-24-000088 Act: 34 Size: 21 MB 网页链接查看全文
Cidara Therapeutics(CDTX)06-12 06:35
$Cidara Therapeutics(CDTX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001628280-24-027720 Size: 7 KB 网页链接查看全文
Cidara Therapeutics(CDTX)07-20 04:45
$Cidara Therapeutics(CDTX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001610618-24-000093 Size: 6 KB 网页链接查看全文
Cidara Therapeutics(CDTX)07-20 05:05
$Cidara Therapeutics(CDTX)$ S-1 General form for registration of securities under the Securities Act of 1933 Accession Number: 0001193125-24-181693 Act: 33 Size: 259 KB 网页链接查看全文
Cidara Therapeutics(CDTX)07-20 05:05
$Cidara Therapeutics(CDTX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001610618-24-000108 Size: 5 KB 网页链接查看全文
SeekingBiotech04-25 22:03
CDTX entered into an asset purchase agreement with its current partner, Mundipharma, for the divestiture of rezafungin. Cidara estimates that it will achieve approximately $128 million in cost savings over the patent life of rezafungin comprising approximately $67 million in ...查看全文
牛唐2023-09-11 17:23
医药板块速评（2023.09.08）
1、心脏病领域的基因疗法企业有哪些值得关注？
2、与强生合作的$Cidara Therapeutics(CDTX)是否存在翻盘机会？
3、$葛兰素史克(GSK)$ 、$百时美施贵宝(BMY)$ 、$英特尔(INTC)$ 、$花旗集团(C)、$西方石油(OXY)、$Kenvue(KVUE)期权大量成交，后续走势如何看查看全文
SeekingBiotech2023-04-25 08:45
CDTX Receives $20M Milestone Payment Following FDA Approval of REZZAYO$Cidara Therapeutics(CDTX)$查看全文
SeekingBiotech2023-03-24 02:10
Cidara Therapeutics gets FDA approval of Rezzayo for the treatment of Candidemia and Invasive Candidiasis in adults. 抗真菌。$Cidara Therapeutics(CDTX)$查看全文
产业链观察2023-03-02 19:15
#药闻简讯# 2023年3月1日--开发旨在帮助提高面临严重疾病的患者的护理标准的长效疗法的生物技术公司$Cidara Therapeutics(CDTX)$ 今天宣布，正在进行的评估CD388对H3N2甲型流感病毒株的暴露前预防活性的2a期试验的计划中期分析的疗效和安全性数据，截至2023年2月13日的数据截止。
动物疗效研究...查看全文
SeekingBiotech2023-01-28 21:25
新一代棘白菌素药物---雷扎芬净（Rezafungin），抗真菌领域。即将获批上市。Cidara/Melinta Therapeutics/Mundi$Cidara Therapeutics(CDTX)$查看全文
chuminhua2023-01-26 11:09
1月25日，FDA 咨询委员会同意 Cidara Therapeutics 每周一次的抗真菌治疗药物 rezafungin 应该在某些情况下获得治疗念珠菌真菌感染的批准。 该小组以 14 票对 1 票的投票结果表明，Cidara 在其 FDA 备案中提供了足够的证据，表明该药物在成人念珠菌血症和侵袭性念珠菌病中的益处大于其风险，而且几...查看全文
SeekingBiotech2022-10-05 09:43
Cidara Therapeutics (CDTX) Receives $11.1M Milestone Payment from Mundipharma.
rezafungin. 抗真菌$Cidara Therapeutics(CDTX)$查看全文
产业链观察2022-07-27 20:30
药闻▶$Cidara Therapeutics(CDTX)$ 提交Rezafungin的NDA并宣布与Melinta Therapeutics达成Rezafungin在美国商业化的许可协议。Cidara将获得3000万美元的预付现金查看全文
andrewmed2021-04-07 09:23
文章来源：“凯莱英药闻”微信公众号
美国东部时间4月5日，纳斯达克上市公司Cidara Therapeutics宣布与跨国制药巨头强生就抗甲型/乙型流感病毒药物开发达成一项总价值7.8亿美元的合作，预付款2700万美元。
合作内容包含Cidara旗下抗病毒偶联药物（antiviral conjugates，AVCs)）如CD388、C...查看全文
$CIDARA THERAPEUTICS INC COM USD0.0001(CDTX)$ SC 13G - Statement of acquisition of beneficial ownership by individuals Filed: 2016-05-17 AccNo: 0000950142-16-003743 Size: 230 KB 网页链接
$CIDARA THERAPEUTICS INC COM USD0.0001(CDTX)$ 8-K - Current report Filed: 2016-05-12 AccNo: 0001564590-16-019256 Size: 144 KBItem 2.02: Results of Operations and Financial ConditionItem 9.01: Financial Statements and Exhibits 网页链接
$CIDARA THERAPEUTICS INC COM USD0.0001(CDTX)$ 10-Q - Quarterly report [Sections 13 or 15(d)] Filed: 2016-05-12 AccNo: 0001564590-16-019260 Size: 3 MB 网页链接
$CIDARA THERAPEUTICS INC COM USD0.0001(CDTX)$ DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material Filed: 2016-04-29 AccNo: 0001564590-16-017158 Size: 201 KB 网页链接
$CIDARA THERAPEUTICS INC COM USD0.0001(CDTX)$ DEF 14A - Other definitive proxy statements Filed: 2016-04-29 AccNo: 0001564590-16-017156 Size: 1 MB 网页链接
$CIDARA THERAPEUTICS INC COM USD0.0001(CDTX)$ DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material Filed: 2016-04-29 AccNo: 0001564590-16-017158 Size: 201 KB 网页链接
$CIDARA THERAPEUTICS INC COM USD0.0001(CDTX)$ DEF 14A - Other definitive proxy statements Filed: 2016-04-29 AccNo: 0001564590-16-017156 Size: 1 MB 网页链接
$CIDARA THERAPEUTICS INC COM USD0.0001(CDTX)$ 美东时间 2016-04-12 15:00 Cidara Therapeutics Inc at Needham Healthcare Conference 网页链接
$CIDARA THERAPEUTICS INC COM USD0.0001(CDTX)$ 美东时间 2016-04-12 15:00 Cidara Therapeutics Inc at Needham Healthcare Conference 网页链接
$CIDARA THERAPEUTICS INC COM USD0.0001(CDTX)$ SC 13G - Statement of acquisition of beneficial ownership by individuals Filed: 2016-04-04 AccNo: 0001193125-16-529456 Size: 62 KB 网页链接